Dual PI3K/mTOR inhibitors: does p53 modulate response?

Oleksandr Ekshyyan; Arunkumar Anandharaj; Cherie-Ann O Nathan

doi:10.1158/1078-0432.CCR-13-1291

Dual PI3K/mTOR inhibitors: does p53 modulate response?

Clin Cancer Res. 2013 Jul 15;19(14):3719-21. doi: 10.1158/1078-0432.CCR-13-1291. Epub 2013 Jun 5.

Authors

Oleksandr Ekshyyan¹, Arunkumar Anandharaj, Cherie-Ann O Nathan

Affiliation

¹ Department of Otolaryngology/Head and Neck Surgery and Feist-Weiller Cancer Center, LSU Health Sciences Center, Shreveport, Louisiana 71130, USA.

PMID: 23741068
DOI: 10.1158/1078-0432.CCR-13-1291

Abstract

Head and neck squamous cell carcinomas have multiple genetic alterations that can influence clinical response to treatment. It is important to evaluate how distinct alterations affect response to targeted agents to identify a subset of patients who can benefit from therapy, improving survival and decreasing toxicity.

Publication types

Comment

MeSH terms

Animals
Antineoplastic Agents / pharmacology*
Carcinoma, Squamous Cell / therapy*
Female
Head and Neck Neoplasms / therapy*
Humans
Pyridones / pharmacology*
Pyrimidines / pharmacology*
Tumor Suppressor Protein p53 / genetics*

Substances

2-amino-8-(4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido(2,3-d)pyrimidin-7(8H)-one
Antineoplastic Agents
Pyridones
Pyrimidines
TP53 protein, human
Tumor Suppressor Protein p53